French pharmaceutical company Sanofi has reached an agreement to acquire Dynavax Technologies Corporation (Dynavax), a US laboratory that markets a vaccine against hepatitis B for adults (HEPLISAV-B) and a candidate against shingles, for the equivalent of 1.867 billion euros.